Laurus Labs Ltd
LAURUSLABSLaurus Labs Ltd
LAURUSLABS
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 157.83 | 5.68 | 0.18% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 13 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,781.94 | 1,937.03 | 2,085.36 | 2,308.07 | 2,837.64 | 4,837.17 | 4,950.87 | 6,046.55 | 5,067.17 | 5,079.20 | ||||||||||
Raw Materials | 1,033.24 | 1,031.67 | 1,088.41 | 1,267.63 | 1,629.55 | 2,455.20 | 2,414.94 | 2,752.28 | 2,533.30 | 4,271.97 | ||||||||||
| Power & Fuel Cost | 57.96 | 66.27 | 94.21 | 109.37 | 136.77 | 157.75 | 204.47 | 324.10 | 338.15 | |||||||||||
| Employee Cost | 175.46 | 204.73 | 238.14 | 276.33 | 320.77 | 397.04 | 469.55 | 557.43 | 614.85 | |||||||||||
| Selling & Administrative Expenses | 67.97 | 92.25 | 96.07 | 140.99 | 189.38 | 239.88 | 276.15 | 291.01 | 335.07 | |||||||||||
| Operating & Other expenses | 80.75 | 102.10 | 126.03 | 141.61 | -9.30 | 12.96 | 148.03 | 523.54 | 441.96 | |||||||||||
EBITDA | 366.56 | 440.01 | 442.50 | 372.14 | 570.47 | 1,574.34 | 1,437.73 | 1,598.19 | 803.84 | 807.23 | ||||||||||
| Depreciation/Amortization | 86.41 | 105.98 | 125.45 | 164.19 | 187.27 | 205.07 | 251.49 | 324.08 | 384.58 | 400.09 | ||||||||||
| PBIT | 280.15 | 334.03 | 317.05 | 207.95 | 383.20 | 1,369.27 | 1,186.24 | 1,274.11 | 419.26 | 407.14 | ||||||||||
| Interest & Other Items | 111.11 | 99.90 | 79.64 | 88.19 | 89.59 | 68.16 | 102.39 | 165.17 | 182.90 | 192.90 | ||||||||||
| PBT | 169.04 | 234.13 | 237.41 | 119.76 | 293.61 | 1,301.11 | 1,083.85 | 1,108.94 | 236.36 | 214.24 | ||||||||||
| Taxes & Other Items | 35.30 | 43.86 | 69.81 | 25.99 | 38.34 | 317.53 | 256.33 | 318.83 | 75.81 | 66.03 | ||||||||||
| Net Income | 133.74 | 190.27 | 167.60 | 93.77 | 255.27 | 983.58 | 827.52 | 790.11 | 160.55 | 148.21 | ||||||||||
| EPS | 0.86 | 1.81 | 3.17 | 1.77 | 4.79 | 18.36 | 15.41 | 14.69 | 2.98 | 2.75 | ||||||||||
| DPS | 0.10 | 0.30 | 0.30 | 0.30 | 0.50 | 2.00 | 2.00 | 2.00 | 0.80 | 0.80 | ||||||||||
| Payout ratio | 0.12 | 0.17 | 0.09 | 0.17 | 0.10 | 0.11 | 0.13 | 0.14 | 0.27 | 0.29 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Laurus Labs Ltd | 145.70 | 5.68 | 0.18% |
| Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
| Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
| Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare LAURUSLABS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.12%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 2.50%
Top 5 Mutual Funds holding Laurus Labs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.0586% | Percentage of the fund’s portfolio invested in the stock 1.27% | Change in the portfolio weight of the stock over the last 3 months 0.68% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/108 (+10) |
Mirae Asset ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.7387% | Percentage of the fund’s portfolio invested in the stock 1.80% | Change in the portfolio weight of the stock over the last 3 months 0.52% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 49/93 (+6) |
Mirae Asset Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9412% | Percentage of the fund’s portfolio invested in the stock 1.43% | Change in the portfolio weight of the stock over the last 3 months 0.30% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/88 (+6) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
LAURUSLABS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.18%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.84 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateMay 8, 2024
Dividend/Share
₹0.40
Ex DateEx Date
May 8, 2024
Cash Dividend
Ex DateEx DateNov 2, 2023
Dividend/Share
₹0.40
Ex DateEx Date
Nov 2, 2023
Cash Dividend
Ex DateEx DateMay 10, 2023
Dividend/Share
₹1.20
Ex DateEx Date
May 10, 2023
Cash Dividend
Ex DateEx DateNov 3, 2022
Dividend/Share
₹0.80
Ex DateEx Date
Nov 3, 2022
Cash Dividend
Ex DateEx DateMay 10, 2022
Dividend/Share
₹1.20
Ex DateEx Date
May 10, 2022
Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and Cyient
Laurus Labs Q1 net slumps to ₹13 crore on lower revenue
Board of Laurus Labs appoints director
The Board of Laurus Labs at its meeting held on Ramesh Subrahmanian (DIN: 02933019) as an Additional Director in the capacity of Independent Director of the Company with effect from 25 July 2024 for a tenure of 5 years, , subject to approval of the shareholders.Powered by Capital Market - Live
Laurus Labs consolidated net profit declines 49.66% in the June 2024 quarter
Net profit of Laurus Labs declined 49.66% to Rs 12.51 crore in the quarter ended June 2024 as against Rs 24.85 crore during the previous quarter ended June 2023. Sales rose 1.11% to Rs 1194.91 crore in the quarter ended June 2024 as against Rs 1181.79 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1194.911181.79 1 OPM %14.3314.11 - PBDT124.52131.13 -5 PBT18.4640.58 -55 NP12.5124.85 -50 Powered by Capital Market - Live
Stock alert: Axis Bank, Larsen & Toubro, SBI Life Insurance Company, J K Paper, Bikaji Foods, Oracle Financal Services Software
Q1 results today: Nestle, Tech Mahindra among 76 companies to announce earnings on Thursday
Laurus Labs will hold a meeting of the Board of Directors of the Company on 25 July 2024.Powered by Capital Market - Live
Laurus Labs Ltd up for third consecutive session
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.03%, vs industry avg of 8.96%
Increasing Market Share
Over the last 5 years, market share increased from 1.02% to 1.38%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 11.35%, vs industry avg of 15.15%